Aap Implantate : Publication of annual financial statements 2020 on 30 April 2021
March 10, 2021 at 07:07 am EST
Share
DGAP-News: aap Implantate AG
/ Key word(s): Annual Report/Annual Results
Publication of annual financial statements 2020 on 30 April 2021
10.03.2021 / 13:04
The issuer is solely responsible for the content of this announcement.
aap Implantate AG ("aap") announces that the publication of the annual and consolidated financial statements 2020 will take place on 30 April 2021. On this date, the annual financial report 2020 (HGB) and the consolidated annual financial report 2020 (IFRS) will be published.
----------------------------------------------------------------
aap Implantate AG (ISIN DE0005066609) - General Standard/Regulated Market - All German stock markets -
About aap Implantate AG aap Implantate AG is a globally active medical technology company based in Berlin, Germany. The Company develops, manufactures and markets products for trauma. The IP-protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) a wide range of cannulated screws. In addition, aap Implantate AG has an innovation pipeline with promising development projects such as the antibacterial silver coating technology and magnesium-based implants. These technologies address critical and unmet needs in trauma. In Germany, aap Implantate AG sells its products directly to hospitals, purchasing groups, and hospital groups, while at international level it primarily uses a broad network of distributors in around 25 countries. In the US the Company pursues a hybrid distribution strategy with its subsidiary aap Implants Inc. Distribution is carried out both through distribution agents and partnerships with global orthopedic companies. aap Implantate AG's stock is listed in the General Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit our website at www.aap.de.
Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.
10.03.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Language:
English
Company:
aap Implantate AG
Lorenzweg 5
12099 Berlin
Germany
Phone:
+49 (0) 30 75 01 90
Fax:
+49 (0) 30 75 01 91 11
E-mail:
info@aap.de
Internet:
www.aap.de
ISIN:
DE000A3H2101
WKN:
A3H210
Listed:
Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
aap Implantate AG is a Germany-based provider of medical devices for human muscular and skeletal systems. The Company focuses on trauma and biomaterials products for orthopedics. The Biomaterials portfolio comprises bone substitutes for the filling of aseptic bone defects, bone cements and accessories for the application in arthroplasty, bone cements and accessories for the application in vertebroplasty and kyphoplasty. The trauma portfolio includes a wide range of cannulated screws, standard plates and screws for miniature, small and large bone fragments, among others . It also develops LOQTEQ, a technology that allows for fracture compression with subsequent locking fixation in one surgical step. The Company operates a network of distributors in more than 60 countries, and cooperates directly with physicians and hospital customers.
AAP IMPLANTATE AG 
